1. Background {#sec201999}
=============

Non-fermenting Gram-negative bacterial pathogens (NFGNBPs) are a common cause of opportunistic infections in critically ill or immunocompromised patients ([@A35624R1]). NFGNBPs are commonly responsible for infections in intensive care units (ICUs) ([@A35624R2]), and they have been associated with prolonged hospitalization, considerable costs, and notable mortality and morbidity ([@A35624R3], [@A35624R4]).

The treatment of Gram-negative organisms represents a great challenge for the healthcare community ([@A35624R2], [@A35624R3]), mainly due to the significant increase in resistance to antimicrobial agents. Antimicrobial resistance among Gram-negative pathogens is a growing problem and a global concern ([@A35624R2], [@A35624R5]), as traveling and trading permits the spread of resistant pathogens among countries and continents ([@A35624R5]). Important NFGNBPs in the United States are *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Stenotrophomonas maltophilia*, and *Burkholderia cepacia* ([@A35624R1]). Two multidrug-resistant (MDR) non-fermenting Gram-negative pathogens of great importance presently are *A. baumannii* and *P. aeruginosa*([@A35624R1], [@A35624R6]).

In recent decades, *A. baumannii* has been recognized as a leading nosocomial pathogen, particularly among patients admitted to the ICU ([@A35624R6], [@A35624R7]). In the past, most *A. baumannii* isolates were sensitive to carbapenems ([@A35624R7]), but in the last two decades, due to the widespread use of these antibiotics, MDR and extensively drug-resistant (XDR) strains of *A. baumannii* have been increasingly reported and have emerged as a critical problem worldwide ([@A35624R8], [@A35624R9]). Members of the genus *Acinetobacter* have been implicated as the cause of many serious infectious diseases, such as respiratory infections, bacteremia, urinary tract infections, meningitis, and endocarditis, mostly engaging critically ill or immunocompromised patients ([@A35624R1], [@A35624R8]). The incidence of *A. baumannii* infections has increased over the last few decades ([@A35624R10]) and this has been recognized as the third most common causative agent of infections in ICU patients, with mortality rates of 26% - 68% ([@A35624R7]). The outcomes of patients with MDR or XDR *A. baumannii* infections seem to be worse ([@A35624R10]).

*Pseudomonas aeruginosa*is considered one of the major causes of opportunistic infections ([@A35624R6]) and is recognized as a common cause of morbidity and mortality among hospitalized patients in the United States ([@A35624R1]). *Pseudomonas aeruginosa*is recognized as the main cause of a wide range of healthcare-associated infections, especially in immunocompromised patients and those with cystic fibrosis ([@A35624R6]). This bacterium is distinguished by a high intrinsic resistance to antibiotics; it can also acquire resistance to the antibiotics used, and therefore its antibacterial resistance rate continues to increase ([@A35624R1]).

2. Objectives {#sec202000}
=============

The aim of this study was to assess the prevalence and pattern of antibiotic resistance in *A. baumannii* and *P. aeruginosa* isolates collected from ICUs at Imam Khomeini hospital in Ahvaz, Iran, in order to provide essential information for a more rational use of broad-spectrum antibiotics and to justify infection-control protocols in order to restrict the spread of MDR bacteria and NFGNBPs.

3. Methods {#sec202004}
==========

3.1. Bacterial Isolates {#sec202001}
-----------------------

This study was conducted in ICUs at Imam Khomeini hospital, a teaching hospital associated with Ahvaz Jundishapur University of Medical Sciences, from January 1 to December 30, 2013. During this time, a total of 2.174 patients were admitted to the various ICUs of this hospital, and 552 clinical specimens were collected from these patients. The ICUs included the surgical ICU, the internal medicine ICU, the cardiovascular ICU, the coronary care unit (CCU), and the neonatal intensive care unit (NICU). Patients who had taken prophylactic antibiotics were excluded from the study.

The isolates were obtained from a wide range of clinical specimens, including blood, pleural fluid, urine, tracheal tube discharge, secretions, wounds, abscesses, eyes (cornea, conjunctivae, foreign bodies, lenses, etc.), surgical wounds, cerebrospinal fluid, ascites, pericardial fluid, and articular fluids. The clinical specimens were obtained in accordance with the standard guidelines ([@A35624R11]).

Laboratory tests for different specimens were performed as follows: blood and eosin-methylene blue (EBM) agar plates were used for urine specimens; trypticase soy broth (TSB) followed by sub-culturing for blood and MacConkey agar plates were used for blood specimens; and blood, MacConkey agar plates, and sodium thioglycollate broth were used for other specimens. Each specimen was incubated at 35°C for 24 - 48 hours on its specific agar plate in order to boost bacterial growth ([@A35624R11]).

The agar plates used in this study were obtained from Merck KGaA (Darmstadt, Germany) and *Laboratorios Conda* (Canada). Quality control was performed with *Escherichia coli* ATCC 25922, *Staphylococcus* ATCC 25923, *P. aeruginosa*ATCC 27853, and *Enterococci* ATCC 29212. All of the suspected colonies were evaluated with Gram-staining, colonial morphology, oxidation-fermentation testing, ortho-Nitrophenyl-β-galactoside (ONPG) testing, and other biochemical reactions ([@A35624R11], [@A35624R12]). The suspected colonies were identified as *A. baumannii* if they were oxidase- and nitrate-negative, while having dextrose-positive reactions and growing at 44°C ([@A35624R11]).

3.2. Antimicrobial Susceptibility Testing {#sec202002}
-----------------------------------------

Antimicrobial susceptibility of the isolated organisms was evaluated by the disk diffusion method in accordance with clinical laboratory and standards institute (CLSI) guidelines ([@A35624R13]). Concisely, a suspension of each isolate was assembled so that the turbidity was equal to 0.5 McFarland standards, and was then cultivated onto Mueller-Hinton agar. After 18 24 hours of incubation at 35°C, the inhibition zone diameter was measured, the collected data were compared to CLSI standards, and each isolate was eventually reported as susceptible, intermediate, or resistant ([@A35624R13]). The antibiotic disks used in this study were obtained from Padtan Teb (Iran) and ROSCO (Denmark).

An *Acinetobacter* isolate was defined as MDR if it was resistant to all generations of cephalosporins, fluoroquinolones, and aminoglycosides. XDR *Acinetobacter* was defined as non-susceptibility to cephalosporins, fluoroquinolones, aminoglycosides, and carbapenems ([@A35624R14]).

3.3. Data Management and Statistical Analysis {#sec202003}
---------------------------------------------

The data for antimicrobial susceptibility testing were managed and converted into a standard format using WHONET software (version 5.6, WHO, Switzerland) and were statistically analyzed with SPSS software (version 19, SPSS Inc., Chicago, IL, USA). A two-tailed P value of \< 0.05 was considered statistically significant. This study was approved by the ethics committee of the school of medicine, Ahvaz Jundishapur University of Medical Sciences.

4. Results {#sec202005}
==========

A total of 155 clinical isolates of NFGNBPs, including 80 (51.6%) isolates of *A. baumannii* and 75 (48.4%) isolates of *P. aeruginosa*, were obtained from patients hospitalized in the ICUs of Imam Khomeini Hospital in Ahvaz, Iran. *A. baumannii* and *P. aeruginosa*were most frequently isolated from the surgical ICU (18.06%) and the internal medicine ICU (25.80%), respectively ([Table 1](#tbl51119){ref-type="table"}). The most common source of *Acinetobacter* and *P. aeruginosa*isolates was tracheal secretions (47.5%, and 52%, respectively). [Figure 1](#fig37232){ref-type="fig"} shows the distribution of isolates from different specimen sites.

###### Prevalence of Each Organism Among 155 Clinical Specimens Isolated from Different ICU Wards

  Organism                        Prevalence of Isolates among Specimens from all ICU Wards, %   Prevalence of Each Organism in Different Wards, %                          
  ------------------------------- -------------------------------------------------------------- --------------------------------------------------- ------ ------- ------- ------
  ***Acinetobacter baumannii***   51.6                                                           0.64                                                6.45   16.77   18.06   9.67
  ***Pseudomonasaeruginosa***     48.4                                                           0                                                   3.22   25.80   14.19   5.16

Abbreviations: CCU, coronary care unit; CVICU, cardiovascular ICU; ICU, intensive care unit; IMICU, internal medicine ICU; NICU, neonatal intensive care unit; SICU, surgical ICU.

![Distribution of Isolates in Different Specimen Sites](jjm-09-08-35624-i001){#fig37232}

The maximum *Acinetobacter* resistance rates were observed for ciprofloxacin and trimethoprim-sulfamethoxazole (96.9% and 95.2%, respectively). The results of antibiotic susceptibility testing for *Acinetobacter* isolates are shown in [Table 2](#tbl51120){ref-type="table"}. Among 80 *Acinetobacter* isolates, 65 were XDR (81.3%), one was MDR (1.2%), and 14 were susceptible (17.5%) to the antimicrobial drugs most commonly used in ICU settings.

###### Results for Antibiotic Susceptibility Testing of 80 *A. baumannii* Isolates

  Antibiotic                          Resistant, %   Intermediate, %   Susceptible, %
  ----------------------------------- -------------- ----------------- ----------------
  **Amikacin**                        84.8           0                 15.2
  **Cefepime**                        84.7           5.6               9.7
  **Ceftriaxone**                     92.9           6.5               1.3
  **Ciprofloxacin**                   96.9           0                 3.1
  **Tetracycline**                    81.8           18.2              0
  **Trimethoprim-sulfamethoxazole**   95.2           0                 4.8
  **Meropenem**                       88.5           0                 11.5
  **Ampicillin-sulbactam**            42.4           18.6              39

The maximum *P. aeruginosa*resistance rates were reported to ceftriaxone and trimethoprim-sulfamethoxazole (97.2% and 92.4% respectively). The results of antibiotic susceptibility testing of *P. aeruginosa*isolates are shown in [Table 3](#tbl51121){ref-type="table"}. There was no statistically significant difference in antimicrobial resistance between the genders, but a statistical analysis showed a significant difference in antimicrobial resistance among different ICU wards. The NICU had a remarkably lower resistance to three antibacterial agents (amikacin, cefepime, and meropenem; P \< 0.0001) in comparison to the other ICUs.

###### Results of Antibiotic Susceptibility Testing of 75 *P. aeruginosa*Isolates

  Antibiotic                          Resistant, %   Intermediate, %   Susceptible, %
  ----------------------------------- -------------- ----------------- ----------------
  **Amikacin**                        73.5           4.4               22.1
  **Cefepime**                        77.6           6.9               15.5
  **Ceftriaxone**                     97.2           1.4               1.4
  **Ciprofloxacin**                   68.2           6.1               25.8
  **Gentamicin**                      85.7           0                 14.3
  **Piperacillin**                    57.1           0                 42.9
  **Piperacillin-tazobactam**         46.9           0                 53.1
  **Tetracycline**                    50             16.7              33.3
  **Trimethoprim-sulfamethoxazole**   92.4           1.5               6.1
  **Meropenem**                       64.3           4.3               31.4
  **Ceftazidime**                     71.2           7.6               21.2

5. Discussion {#sec202006}
=============

Infections in ICUs are a formidable healthcare concern ([@A35624R15]), in particular the MDR *A. baumannii* and *P. aeruginosa*infections that have become increasingly common over the last few decades, especially among critically ill or immunocompromised patients ([@A35624R16]). This resistance to common antibiotic agents may lead to outbreaks that can be very challenging for healthcare personnel to control.

There have been relatively few studies on antibiotic resistance patterns of NFGNBPs in ICUs in Iran. In 2009, Vahdani et al. ([@A35624R10]) reported an *A. baumannii* resistance rate of 85% to ciprofloxacin and co-trimoxazole and a 58% resistance rate to amikacin in Tehran. The present study revealed a higher resistance to these antibiotics (96.9% for ciprofloxacin, 95.2% for co-trimoxazole, and 84.8% for amikacin).

The results of a study that Shoja et al. ([@A35624R7]) carried out on the ICUs of two hospitals in the city of Ahvaz from 2010 to 2012 showed that the resistance rate of *A. baumannii* to meropenem was 96.1%. The findings of the present study indicate a marked reduction in this rate, to 88.5%. In comparison to Shoja et al.'s study, our results also showed lower resistance rates to ceftriaxone (92.9% versus 96.1%), cefepime (84.7% versus 96.1%), and ampicillin-sulbactam (42.4% versus 69.4%), as well as lower susceptibility to tetracycline (0% versus 7.3%), and trimethoprim-sulfamethoxazole (4.8% versus 7.8%). This marked difference in *Acinetobacter* resistance might be due to the fact that Shoja et al. did not include NICU specimens, as we did in the present study.

In 2013, Nasrolahei et al. ([@A35624R8]) evaluated 100 *A. baumannii* isolates from burn patients and ICU patients in Tehran and Sari, and reported that 37.1% of *A. baumannii* isolates were XDR. The present study revealed a markedly higher rate of XDR *A. baumannii* isolates (81.3%). In 2013, Salehi et al. ([@A35624R17]) conducted a study on the antimicrobial resistance pattern of clinical isolates of *P. aeruginosa*from patients hospitalized in trauma and burn ICUs in Tehran; they reported resistance rates of 82.2% for ceftriaxone, 44.9% for piperacillin, and 48.03% for tetracycline. The present study revealed substantially higher resistance rates to these antibiotics (97.2%, 57.1%, and 50%, respectively). This analysis revealed that there has been an overall increase in the antibiotic resistance pattern of *P. aeruginosa*.

In 2011, Sader et al. reviewed the antimicrobial susceptibility patterns of 5,989 Gram-negative bacterial isolates from ICU patients in hospitals in the United States and Europe (3). The results for *A. baumannii* isolates in the United States revealed susceptibility rates of 51.8% to amikacin, 42.8% to ampicillin-sulbactam, 33.7% to cefepime, 34.3% to ciprofloxacin, and 42.8% to meropenem. The results for *A. baumannii* isolates in Europe showed susceptibility rates of 51.1% to amikacin, 30.2% to ciprofloxacin, and 43.2% to meropenem; these were all shown to be remarkably lower in the present study ([Table 2](#tbl51120){ref-type="table"} shows the susceptibility rates to different antibiotic agents among *A. baumannii* isolates). The results for *P. aeruginosa*isolates in the United States showed susceptibility rates of 94.8% to amikacin, 91.4% to cefepime, 84.6% to ceftriaxone, 87.3% to ciprofloxacin, 92.7% to gentamicin, 85.9% to piperacillin-tazobactam, and 95.4% to meropenem. The results for *P. aeruginosa*isolates in Europe showed susceptibility rates of 90.5% to amikacin, 76.7% to cefepime, 73.7% to ceftriaxone, 76.3% to ciprofloxacin, 83.3% to gentamicin, 71.4% to piperacillin-tazobactam, and 95.8% to meropenem. The susceptibility rates for *P. aeruginosa*were significantly lower in the present study ([Table 3](#tbl51121){ref-type="table"}).

To our knowledge, there are few studies investigating the relationship of independent factors with NFGNBP resistance rates. In this study, we evaluated NFGNBP resistance rates according to the patients' genders, and found no statistically significant differences. However, the results of a study conducted by Xu et al. ([@A35624R18]) in China to investigate the antimicrobial resistance of *A. baumannii* showed a higher antimicrobial resistance to five antibiotics in males.

We also analyzed the NFGNBP resistance rate according to different ICU wards. Statistically significant differences in NFGNBP resistance were reported among three drugs (amikacin, cefepime, and meropenem; P \< 0.0001). It is noteworthy that all of the NFGNBP resistance rates were significantly lower in the NICU. This might be due to different types of bacteria isolated in the NICU compared to other ICUs, which is attributed to different antibiotic policies and different antibacterial resistance patterns. Ariffan et al. ([@A35624R19]) also reported a lower antibacterial resistance in NICUs compared to adult ICUs.

The present study revealed a high number of *A. baumannii* and *P. aeruginosa*strains with resistance to virtually all antibiotics tested. The marked increase in the number of XDR *A. baumannii* strains and the significant reduction in susceptibility patterns for *P. aeruginosa*emphasize the evolving need for a more rational use of broad-spectrum antibiotics, in addition to an immediate reconsideration of infection-control protocols, in order to restrict the spread of these pathogens.

It should be noted that our data were obtained from only one hospital, so the continuous supervision of antimicrobial resistance of NFGNBPs in Ahvaz is an evolving necessity in order to produce adequate representative data. Further studies are recommended, focusing on various independent factors affecting antibacterial resistance, including age, gender, and different hospital wards.
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